uniQure (NASDAQ:QURE) Releases Earnings Results, Beats Estimates By $0.04 EPS

uniQure (NASDAQ:QURE) announced its quarterly earnings results on Wednesday. The biotechnology company reported ($0.88) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.92) by $0.04, FiscalAI reports. uniQure had a negative return on equity of 111.96% and a negative net margin of 1,350.73%. The firm had revenue of $5.20 million for the quarter, compared to the consensus estimate of $6.17 million.

Here are the key takeaways from uniQure’s conference call:

• The FDA accepted uniQure’s BLA for AMT-130 and granted Priority Review, setting a target decision date of May 1, 2027; the U.K. regulator also validated the company’s marketing application. The FDA is tentatively planning an advisory committee discussion, but approval is not assured.
• Management highlighted prior AMT-130 results showing a reported 75% slowing of disease progression on cUHDRS and 60% on Total Functional Capacity at 36 months versus a matched external control. The company also cited follow-up through 48 months, while noting the evidence comes from a small number of patients.
• The planned confirmatory study will enroll about 200 patients, randomize them 2:1 to AMT-130 or standard of care, and assess TFC at 36 months; screening is expected to begin by year-end. UniQure says it is preparing to have the study well underway by a potential approval, while planning for possible control-arm dropouts and global recruitment.
• Launch preparations are focused on specialist centers, with the company targeting more than 15 operational centers at launch but not yet specifying patient capacity. Management identified center readiness, institutional approvals and payer access as potential factors affecting how quickly patients could receive treatment.
• Cash, cash equivalents and investments totaled $768.4 million at quarter-end, and management expects funding to last into 2030. SG&A increased year over year amid hiring and launch preparations; separately, the company expects updated AMT-260 epilepsy and AMT-191 Fabry data in the first half of 2027.

uniQure Stock Performance

Shares of QURE stock traded down $0.94 during mid-day trading on Wednesday, reaching $22.93. 2,075,046 shares of the company’s stock traded hands, compared to its average volume of 2,411,616. uniQure has a 12 month low of $8.73 and a 12 month high of $51.72. The firm has a 50 day moving average price of $33.57 and a two-hundred day moving average price of $29.69. The company has a debt-to-equity ratio of 0.15, a quick ratio of 10.01 and a current ratio of 10.01. The firm has a market capitalization of $1.59 billion, a PE ratio of -5.71 and a beta of 1.14.

Analyst Ratings Changes

QURE has been the subject of a number of recent analyst reports. Stifel Nicolaus set a $71.00 target price on uniQure in a research report on Wednesday. Royal Bank Of Canada dropped their price target on shares of uniQure from $65.00 to $48.00 and set an “outperform” rating on the stock in a report on Friday, October 2nd. Wells Fargo & Company reiterated an “overweight” rating and issued a $75.00 price target on shares of uniQure in a research note on Tuesday, September 29th. UBS Group assumed coverage on shares of uniQure in a report on Thursday, October 15th. They set a “buy” rating and a $48.00 price objective for the company. Finally, Wall Street Zen downgraded shares of uniQure from a “hold” rating to a “sell” rating in a research report on Saturday, September 5th. One research analyst has rated the stock with a Strong Buy rating, eleven have assigned a Buy rating, three have given a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, uniQure currently has an average rating of “Moderate Buy” and an average price target of $56.83.

About uniQure

uniQure N.V. is a biotechnology company focused on developing gene therapies for serious and life-threatening diseases. The company uses adeno-associated virus (AAV) vectors and other genetic medicine technologies to deliver therapeutic genes intended to address the underlying causes of disease.

uniQure’s best-known product is HEMGENIX, a gene therapy for adults with hemophilia B caused by factor IX deficiency. HEMGENIX was developed by uniQure and is commercialized by CSL Behring under a global licensing agreement.